Nicotinamide for skin cancer chemoprevention in transplant recipients: a critically appraised topic
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad318 ↗Kurz gefasst
Kommentar in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Ashley O Riddle und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Internal Medicine, Dell Medical School, University of Texas, Austin, TX, USA. Hauptthemen laut MEDLINE: Skin Neoplasms, Organ Transplantation. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
This paper critically appraises a phase III trial examining the impact of oral nicotinamide on reducing keratinocyte carcinoma (KC) incidence in solid organ transplant recipients. Despite a well-conducted study finding no significant difference in KC rates between nicotinamide and placebo groups, we suggest that the conclusion could be premature due to the study’s underpowered sample size and lack of analysis on more invasive cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Department of Internal Medicine, Dell Medical School, University of Texas, Austin, TX, USA.
ORCID-Profile: Ashley O Riddle
Zitieren
APA
Riddle, A. O., & Jambusaria-Pahlajani, A. (2023). Nicotinamide for skin cancer chemoprevention in transplant recipients: a critically appraised topic. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad318
Vancouver
Riddle AO, Jambusaria-Pahlajani A. Nicotinamide for skin cancer chemoprevention in transplant recipients: a critically appraised topic. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad318
BibTeX
@article{Riddle2023,
author = {Riddle, Ashley O and Jambusaria-Pahlajani, Anokhi},
title = {Nicotinamide for skin cancer chemoprevention in transplant recipients: a critically appraised topic},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad318}
}
EUVIMED